Monthly Archives: December 2012

Pharmaceutical News: Apeiron, GSK begin phase IIa trial in Acute Lung Injury patients

Posted on December 22, 2012 by Hank

Apeiron, GSK begin phase IIa trial in Acute Lung Injury patients Apeiron Biologics announced that GlaxoSmithKline (GSK), that has licensed Apeiron´s new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has commenced a phase IIa study … Continue reading →

Posted in News | Leave a comment

Pharmaceutical News: Pulmatrix iSPERSE drug delivery system yields positive data

Posted on December 21, 2012 by Hank

Pulmatrix iSPERSE drug delivery system yields positive data Pulmatrix’s iSPERSE inhaled drug platform showed multi-drug delivery abilities and superiority over conventional lactose blending for an effective therapeutic dose of the active ingredients in Advair, salmeterol and fluticasone, as well as … Continue reading →

Posted in Pharmacy | Leave a comment

Pharmaceutical News: Cantor Fitzgerald Analysts Reiterate a “Buy” Rating on Salix Pharmaceuticals (SLXP)

Posted on December 20, 2012 by Hank

Cantor Fitzgerald Analysts Reiterate a “Buy” Rating on Salix Pharmaceuticals (SLXP) Salix Pharmaceuticals (NASDAQ: SLXP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. Separately, analysts at … Continue reading →

Posted in News | Leave a comment

Pharmaceutical News: Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome

Posted on December 19, 2012 by Hank

Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. IPXL +0.11% , announced that it has initiated a Phase IIb trial of its drug candidate IPX159 in … Continue reading →

Posted in News | Leave a comment